CureVac N.V. (Ticker: CVAC) is a clinical-stage biopharmaceutical company pioneering innovative treatments based on messenger RNA (mRNA) technology. Headquartered in Tübingen, Germany, the company plays a key role in the global health technology and biotechnology sectors.
📈 Key Market & Financial Highlights
- Market Capitalization: $1.26 Billion USD
- Price-to-Earnings Ratio (TTM): 4.51
- Basic EPS (TTM): $0.91 USD
- Employees (FY): 983
- Revenue Per Employee (1Y): $588.91K USD
- Net Income Per Employee (1Y): $178.47K USD
Despite being founded in 2020, CureVac has shown strong financial metrics, underpinned by its focused research pipeline and strategic positioning in the mRNA-based therapeutic space.
🧬 Company Overview
CureVac specializes in developing transformative medicines using messenger ribonucleic acid (mRNA). The company’s proprietary platform enables the development of clinical and preclinical candidates for a wide range of diseases, including:
- Prophylactic Vaccines
- Oncology Treatments
- Protein Therapies
CureVac’s innovation lies in harnessing the natural capabilities of mRNA to direct the body’s immune system and cellular processes to prevent or treat diseases effectively.
Leadership & History
- CEO: Alexander Zehnder
- Founders: Ingmar Hoerr and Florian von der Mülbe
- Founded: Originally in 2000 (listed as public entity in 2020)
The company has been at the forefront of mRNA research long before the global spotlight during the COVID-19 pandemic. It was one of the earliest firms to explore mRNA for medical use, laying the groundwork for a new era of biopharmaceutical development.
🌐 Contact & Listings
Official Website: curevac.com
ISIN: NL0015436031
FIGI: BBG00W9LXXJ4
📍 Headquarters
Location: Tübingen, Germany
🌍 Sector & Industry
Sector: Health Technology
Industry: Biotechnology
Conclusion
CureVac (CVAC) represents one of the most promising biotech firms leveraging mRNA to combat global health issues. With a solid leadership team, expanding research pipeline, and increasing market interest in biotechnology, CureVac remains a stock worth watching for investors and analysts alike.
Leave a Reply